Drug Trial Radar · NCT05117242
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
125
Actual
Start
Oct 27, 2021
Primary completion
Dec 2, 2024
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Nov 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare the safety and efficacy (how well the drug works) of acasunlimab (also known as GEN1046) when it is used alone (monotherapy) versus when it is combined with a cancer drug (pembrolizumab) for participants with relapsed/refractory (disease has returned after treatment or did not respond to treatment) non-small cell lung cancer (NSCLC; the most common type of lung cancer). This trial has 2 parts. The purpose of the first part is to find out if the combination of acasunlimab and pembrolizumab is safe and to find out the best doses to use. The purpose of the second part is to give acasunlimab and pembrolizumab to more participants to evaluate efficacy. In the second part of the trial, participants will be randomized to participate in 1 of the 3 arms of the trial. Randomized means that the participant will be randomly assigned to a treatment arm based on chance; no one chooses their treatment arm. Participants will receive either acasunlimab alone (100 followed by 500 mg into the vein) or acasunlimab with pembrolizumab (200 or 400 mg into the vein) once every 3 or 6 weeks, depending on which arm the participant is randomized into. All participants will receive active drug; no one will receive placebo. Trial details include: * The average trial duration for an individual participant will be about 10 months. * The average treatment duration for an individual participant will be about 6 months. * The visit frequency will be weekly at first and lessening over time until visits are only once every 3 weeks.
Conditions
- Non Small Cell Lung Cancer Metastatic
Interventions
AcasunlimabBiological
Acasunlimab will be administered intravenously (IV)
PembrolizumabBiological
Pembrolizumab will be administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: From first treatment to approximately 27 weeks after last subject's first dose
Locations
40 sites in 9 countries. Site status is shown where the registry gives one.
St. Joseph Heritage Healthcare
Santa Rosa, California
Florida Cancer Specialists - FCS South
Fort Myers, Florida
Florida Cancer Center
St. Petersburg, Florida
Henry Ford Cancer Institute
Detroit, Michigan
Cancer & Hematology Centers of Western Michigan CHCWM P.C.
Grand Rapids, Michigan
Medical College of Wisconsin
Milwaukee, Wisconsin
Institut Bergonie
Bordeaux, France
Hopital Morvan CHU de Brest
Brest, France
Hopital Charles Nicolle Chu Rouen
Rouen, France
Hopital dInstruction Des Armees Begin
Saint-Mandé, France
Institut de Cancerologie Strasbourg Europe (ICANS)
Strasbourg, France
Hôpital Foch
Suresnes, France
Gustave Roussy
Villejuif, France
Med.Hochschule Hannover Klinik für Pneumologie
Hanover, Germany
Universitatsklinik Giessen und Marburg Standort Giessen
Hessen, Germany
LKI Lungenfachklinik Immenhausen
Immenhausen, Germany
Department of Internal Medicine II
Regensburg, Germany
Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco
Catania, Italy
IRCCS Istituto Europeo di Oncologia
Milan, Italy
UOC Oncoematologia AOU L.Vanvitelli
Naples, Italy
La Maddalena SPA
Palermo, Italy
IFO Regina Elena
Roma, Italy
Netherlands Cancer Institute
Amsterdam, Netherlands
VU University Medical Center
Amsterdam, Netherlands
Leids Universitair Medisch Centrum
Leiden, Netherlands
Erasmus MC
Rotterdam, Netherlands
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
Olsztyn, Poland
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland
Centro Clinico Champalimaud
Lisbon, Portugal
Centro Hospitalar Universitário do Porto - Hospital de Santo Antonio
Porto, Portugal
Hospital Universitari Vall dHebron
Barcelona, Spain
Clinica Universidad de Navarra CUN
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
MD Anderson Cancer Center
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Fundacion Instituto Valenciano de Oncologia
Valencia, Spain
Cheltenham General Hospital
Cheltenham, United Kingdom
The Christie Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.